B
Bull
Bull · 25%RNAZ
$12.58
Precio del escenario
$2.180
-0.096 (-4.39%)Al cierre
Loading chart…
- High
- 2.345
- Open
- 2.240
- VWAP
- 2.21
- Vol
- 38.03K
- Mkt Cap
- 7.34M
- Low
- 2.090
- Amount
- 83.86K
- EV/EBITDA, TTM
- 0.00
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
AI analysis of Transcode Therapeutics Inc (RNAZ)
sellTranscode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 6.667, indicating it is oversold, and a staggering year-to-date change of -70.54%, suggesting a significant decline in value. The forward P/E ratio is 0, indicating no expected earnings, and the stock has a current price of 2.18, which is far below its historical SMA of 7.604. The main risk is the negative net income, which reached -19,510,296 in Q1 2026, reflecting ongoing financial struggles.
Métricas de valoración
The current forward P/E ratio for Transcode Therapeutics Inc (RNAZ) is 0.00, compared to its 5-year average forward P/E of -2.02.
Alphio AI Price Scenarios for RNAZ
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
2.007-10NASDAQ.COMVirax Biolabs Partners with Fosun Diagnostics, Shares Surge
2.007-02NASDAQ.COMBiotech Companies See Significant Stock Gains
- 2.007-01NASDAQ.COM
Biotech Companies See Significant Stock Gains
8.506-11NASDAQ.COMBiotech Companies See Significant Stock Gains
8.506-08PRnewswireTransCode to Host Live Webcast on TTX-MC138 Phase 2a Trial and Pipeline
RNAZ FAQ — answered by Alphio AI
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 6.667, indicating it is oversold, and a staggering year-to-date change of -70.54%, suggesting a significant decline in value. The forward P/E ratio is 0, indicating no expected earnings, and the stock has a current price of 2.18, which is far below its historical SMA of 7.604. The main risk is the negative net income, which reached -19,510,296 in Q1 2026, reflecting ongoing financial struggles.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.